All In Biotech

Drug Trial Radar · NCT04106219

A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma

A Phase 1 Study of Aurora Kinase A Inhibitor LY3295668 Erbumine as a Single Agent and in Combination in Patients With Relapsed/Refractory Neuroblastoma

Last checked: Nov 20, 2026Latest source record: Aug 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

71

Planned (sponsor's estimate)

Start

Jun 11, 2020

Primary completion

Apr 13, 2022

Study completion Aug 2027

Sponsor

Lead sponsor
Eli Lilly and CompanyEli Lilly (LLY)
Sponsor type
Industry
Collaborators
New Approaches to Neuroblastoma Therapy Consortium; Innovative Therapies for Children with Cancer in Europe (ITCC)
First posted
Sep 26, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 2 years, up to 21 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The reason for this study is to see if the study drug LY3295668 erbumine is safe in participants with relapsed/refractory neuroblastoma.

Conditions

  • Neuroblastoma

Interventions

  • LY3295668 ErbumineDrug

    Administered orally.

  • TopotecanDrug

    Administered IV.

  • CyclophosphamideDrug

    Administered IV.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Dose Limiting Toxicities (DLTs)Time frame: Baseline through Cycle 2 (28 Day Cycle)
  2. Overall Response Rate (ORR): Percentage of Participants Who Achieve Complete Response (CR) or Partial Response (PR)Time frame: Baseline through Measured Progressive Disease (Estimated up to 5 Years)
  3. Duration of Response (DoR)Time frame: Date of CR or PR to Date of Disease Progression or Death Due to Any Cause (Estimated up to 5 Years)

Locations

17 sites in 9 countries. Site status is shown where the registry gives one.

  • UCSF Medical Center at Mission Bay

    San Francisco, California

  • Children's Hospital Colorado

    Aurora, Colorado

  • University of Chicago - Comer Children's Hospital

    Chicago, Illinois

  • Dana-Farber Cancer Institute

    Boston, Massachusetts

  • Cincinnati Childrens Hospital Medical Center

    Cincinnati, Ohio

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania

  • Texas Childrens Hospital

    Houston, Texas

  • Perth Children's Hospital

    Perth, Western Australia, Australia

  • UZ Gent

    Ghent, Oost-Vlaanderen, Belgium

  • Institut Curie

    Paris, France

  • Centre Leon Berard

    Lyon, Auvergne-Rhône-Alpes, France

  • Universitätsklinikum Köln

    Cologne, Germany

  • Istituto Nazionale dei Tumori

    Milan, Lombardy, Italy

  • National Cancer Center Hospital

    Chuo-ku, Tokyo, Japan

  • Hospital Infantil Universitario Niño Jesús

    Madrid, Spain

  • Hospital Universitari Vall d'Hebron

    Barcelona, Barcelona [Barcelona], Spain

  • Alder Hey Children's Hospital

    Liverpool, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.